SlideShare a Scribd company logo
1 of 58
Download to read offline
Neuroblastoma
17.10.18
By Dr Animesh Agrawal
Moderator Dr Shagun Misra
Contents
• Introduction
• Clinical Presentation
• Pathology & Risk grouping
• Diagnostic workup
• Prognostic factors
• Management
• Role of Screening
Introduction
• Arise from primitive adrenergic neuroblasts of neural crest
tissue in the sympathetic ganglion.
• 4th most common malignancy in children
• Most common malignancy in children <18 mo
• Median age at diagnosis – 22 months
• Clinical heterogeneity
• Spectrum of disease includes spontaneous maturation to
rapid metastatic disease progression.
• Adrenal medulla (35%)
• Para-spinal ganglia lower thoracic and abdominal (30%)
• Posterior mediastinum (19%)
• Pelvic ganglia (2%)
• Cervical ganglia (1%)
• Metastases
- Bone, bone marrow, liver, lymph node and skin
Location
Clinical presentation
• Pain
- Most common presenting symptom
- Due to local spread &/or metastatic disease
• Abdominal lump
• Respiratory compromise: Esp. in young infants
with massive hepatomegaly.
• Others
- Horner’s syndrome (neck mass)
- Spinal cord compression
- Cytopenias (marrow involvement)
- Blueberry muffin sign (skin involvement)
- Bowel/bladder dysfunction (pelvic mass)
- Opsoclonus–myoclonus syndrome (truncal ataxia
and cerebellar encephalopathy).
- Proptosis/ecchymoses: Orbital mets
• Constitutional symptoms: Anorexia, weight loss, malaise, fever
• Mimic pheochromocytoma:
- Paroxysmal hypertension, palpitations, flushing, and headache.
• Severe watery diarrhea and hypokalemia (due to secretion of
vasoactive intestinal peptide by the tumor)
More than 70% of patients
with neuroblastoma present
with metastases at
diagnosis.
Neuroblastoma vs Wilm’s Tumor
• Median age of presentation for NB is ~1.5 yrs vs > 3 yrs for Wilms
• Neuroblastoma often crosses midline (Wilms does not).
• Wilms patients appear healthy vs. NB patients appear sick
• Neuroblastoma (85%) is more likely to exhibit calcifications vs 5 –
10% in Wilm’s.
• NB rarely metastasizes to the lungs (frequent in Wilm’s tumor).
• Wilms arises from & destroys the kidney; NB displaces the kidney.
Pathology
• Classic subtypes
- Neuroblastoma
- Ganglioneuroblastoma
- Ganglioneuroma
• Neuroblastoma
- Small uniform cells
- Hyperchromatic nuclei & scant cytoplasm
- Homer Wright pseudorosette
- Necrosis and calcification
- Mature & intermediate differentiation
ganglion cells
increasing
differentiation
• Shimada system
- Classified tumors into good or poor prognosis groups
based on:
 Stromal component (Stroma rich or poor)
 Grade of differentiation
- Stroma rich, well differentiated
- Stroma rich, intermixed
- Stroma rich, nodular
- Stroma poor, differentiating
- Stroma Poor, undifferentiated
 MKI (Mitosis – Karyorrhexis Index)
 Age (< 18mo, 18 – 60mo, > 60mo)
Shimada et al. JNCI 1984
Histologic classification
Shimada et al. JNCI 1984
Histologic classification
Histologic classification
• International Neuroblastoma Pathology Committee (INPC)
- Based on the Shimada system with minor modifications
Shimada et al. Cancer 1999
INPC classification: Favorable histology
Age Tumor subtype MKI
Any GNB, nodular* NA
GNB, intermixed NA
GN NA
< 18 mo Poorly differentiated NB Low to Intermediate
Differentiating NB Intermediate
18 - 60 mo Differentiating NB Low
* All nodules of NB must have favourable histology
* Nodule: Presence of grossly discrete masses of stroma-poor Nb trapped in mature matrix
Age Tumor subtype MKI
Age Undifferentiated NB Any
Poorly differentiated NB High
Differentiating NB High
Ganglioneuroblastoma,
nodular*
NA
18 – 60 mo Poorly differentiated NB Low to Intermediate
Differentiating NB Intermediate
≥ 60 mo Differentiating NB Any
*At least one nodule of NB must have unfavourable histology
INPC classification: Unfavorable histology
Diagnosis
Laboratory Evaluation
• Routine haematological investigations
- Hemogram
- Biochemistry
• Increased levels of urinary metabolites of catecholamines,
Vanillylmandelic acid (VMA) Homovanillic acid (HVA)
- Seen in > 90% patients.
• May consider: NSE, Chromogranin A (CgA)
Imaging
• Plain radiographs (calcified abdominal or posterior
mediastinal mass.)
• USG Abdomen
• CE CT/MRI more useful
- Intratumoral calcifications, vascular encasement, or both on
preoperative imaging may help distinguish neuroblastoma
from Wilms tumor
- INRG staging depends on radiological parameters for risk
stratification.
• I-123 MIBG (meta-iodo-benzyl-guanidine) + Tc-99m
bone scans for staging.
Biopsy
• Tissue diagnosis is an essential step, except in cases with
+ve bone marrow and urinary excretion of catecholamine
metabolites.
• IHC and tumor cytogenetics form an integral part of
deciding management.
- MYCN amplification (~ 1/3rd)
- 11q aberrations
- DNA ploidy (hyperdiploid carries a better prognosis)
- 1p deletion (~ 2/3rd)
Other Markers
• NSE & CgA (levels correlate with more advanced disease and
worse prognosis)
• NB84 (highly sensitive; less specific)
• CD56 (diffuse positivity indicates more blastic component)
• S100 (diffuse positivity indicates better differentiation)
Negative for:
• CD45, CD99, EMA, CK, desmin, myogenin
Bone marrow aspiration and biopsy
• Bone marrow involvement is seen in ~ 40% patients at
diagnosis.
• If blood or urine levels of catecholamines are increased, then
finding cancer cells in a bone marrow sample is enough to
diagnose neuroblastoma (without getting a biopsy of the
main tumor).
• INSS recommends two aspirations and biopsies from
bilateral sites; biopsy is not required for infants < 6m age.
Staging
2 main systems
INSS
INRG
• Historically the most commonly used.
• Postoperative system.
• Based on both extent of resection and disease extent.
I Localized; GTR (R0/R1)
IIA Localized; < GTR; N0
IIB Localized; ipsilateral Node +ve (C/L –ve)
III Unresectable disease crossing midline or C/L nodes +ve
IV
Distant spread: Nodes, bone marrow/bone, liver, skin or
others
IV-S
Localized; dissemination limited to skin, liver or marrow
(age < 1y)
International Neuroblastoma Staging system
(INSS)
INSS
• Based on the INSS, COG stratifies patients into Low,
Intermediate and High risk1.
• Further management is decided based on the above.
1. Maris JM, Matthay KK. JCO 1999
Limitations of INSS
• Postoperative system, so pre-operative staging/prognostication
cannot be done.
• In an era with improved systemic and supportive therapy, more
patients now receive neoadjuvant treatment.
• INSS staging is done only after upfront surgical resection. This
is often not possible due to extensive local disease/widespread
metastases.
International Neuroblastoma Risk Group
(INRG) Staging system
L1
Localized tumor not involving vital structures as defined by
the list of IDRFs and confined to one body compartment
L2 Locoregional tumor with presence of one or more IDRFs
M Distant metastatic disease (except stage MS)
MS
Metastatic disease in children < 18 months with metastases
confined to skin, liver, and/or bone marrow (< 10%)
• Preoperative staging and risk assessment.
Image defined risk factors (IDRFs)
• Surgical risk factors identified at diagnosis, such that a complete
resection is unsafe.
• Outlined in a Task Force Report by the INRG1:
- Multi-compartment disease
- Encasement of major vessels
(carotid, vertebral, IJV, subclavian, aorta, SVC/IVC, SMA, celiac trunk, renal
pedicles, iliac vessels)
- Contiguous involvement of other organs/structures
(base of skull, pericardium, diaphragm, kidney, liver, porta hepatis,
hepatoduodenal ligament, duodeno-pancreatic block, mesentery)
- Intraspinal extension (> 1/3rd)
- Airway compression (trachea/principal bronchi)
1. Monclair et al. JCO 2009
INRG Classification system
• Along with staging, the task force also suggested a risk
stratification system integrating several parameters, namely:
• The risk groups are Very low, Low, Intermeditate and High.
Cohn et al. INRG Task Force; JCO 2009
INRG Stage L1 > L2 > M
Age < 18 months
Histologic category GN > GNB > NB
Grade of tumor differentiation Differentiating
N-myc status Not amplified
11q aberrations Absence
Tumor cell ploidy Hyperdiploidy
INRG Classification System
Cohn et al. INRG Task Force; JCO 2009
To summarize..
• Staging can be either INSS based, i.e. post op
- Risk stratification is then based on the COG approach
(older, more commonly followed)
- Low, Intermediate, High
• Or the INRG approach may be used i.e. preoperative
(more recent, gradually being adopted)
- Risk stratification being as proposed by the INRG
- Very Low, Low, Intermediate, High
Prognostic
factor
Favorable Unfavorable
Survival
Favorable Unfavorable
• Age
• Stage
• Pathology
(Shimada)
• Ferritin
• NSE
• Urine
VMA/HVA
• N-myc
• DNA index
• 1p deletion
< 2 yrs
1,2 , 4s
Favourable
<143 ng/ml
<100
<1
single copy
> 1.1
Absent
> 2 yrs
3, 4
Unfavorable
> 143 ng/ml
< 143 ng/ml
> 1
Amplified
1
Present
77%
90-100%
90%
83%
79%
84%
70%
100%
90%
38%
30-50%
23%
19%
10%
44%
5%
10%
10%
* Matthay KK. CA Cancer J Clin 1995
Impact on survival of various prognostic factors
Management
Treatment
Options
• Surgery
• Chemotherapy
• Radiation therapy
• High-dose chemotherapy/radiation therapy and stem cell
transplant (HDC/SCT rescue)
• Retinoid therapy/Immunotherapy
Management: Low Risk
• Low risk (about 50%)
• Surgery alone for stage 1 or 2 disease may be sufficient.
• Short course chemotherapy for symptomatic cord compression
or respiratory compromise; may also consider short course
radiotherapy for this purpose.
• Stage 4S: supportive care or short course of chemotherapy
• Survival - 90-95%
• Patients with MYCN amplification or low DNA index may
require adjuvant therapy, and management should be decided
based on the extent of resection and other risk factors.
• About 10-15% of new cases
• Primary resection + standard dose multiagent chemotherapy
for 4-8 months
• In disease that in unresectable or has instraspinal extension,
neoadjuvant chemotherapy may be given prior to resection to
allow safer and more complete resection.
• Survival > 80%
• Radiotherapy may be indicated for certain patients.
Management: Intermediate Risk
Chemotherapy regimen (COG A3961 PROTOCOL)
Course Day Drugs
1 0 Carboplatin – Etoposide
1 Etoposide
2 Etoposide
2 21 Carboplatin – Cyclophosphamide – Doxorubicin
3 42 Cyclophosphamide – Etoposide
43 Etoposide
44 Etoposide
4 63 Carboplatin – Etoposide – Doxorubicin
64 Etoposide
65 Etoposide
Management: Intermediate Risk
Chemotherapy regimen (contd)
Course Day Drugs
5 84 Cyclophosphamide – Etoposide
85 Etoposide
86 Etoposide
6 105 Carboplatin – Cyclophosphamide – Doxorubicin
7 126 Carboplatin – Etoposide
127 Etoposide
128 Etoposide
8 147 Carboplatin – Etoposide – Doxorubicin
Management: Intermediate Risk
• Patients with favourable histology IR disease receive only the 1st 4 courses.
Chemotherapy regimen (contd)
Management: Intermediate Risk
Drug dosages
Carboplatin 560 mg/m2 or 18 mg/kg iv over 1 hour
Etoposide 120 mg/m2 or 4 mg/kg iv over 2 hours
Cyclophosphamide 1000 mg/m2 or 33 mg/kg iv over 1 hour
Doxorubicin Doxorubicin 30 mg/m2 or 1 mg/kg iv
over 15-60 minutes
COG A3961 protocol
• Four general components
1. Induction chemotherapy
2. Surgical resection of all gross disease
3. Consolidation therapy- which generally includes
Myeloablative chemotherapy with stem cell rescue and
Radiation to the tumor bed.
4. Management of Minimal Residual Disease
• Radiotherapy
- Local RT for bulky primary (complementary to surgery)
- TBI: as part of myeloablative conditioning regimen if
HDC/ASCT is planned.
Management: High Risk
Surgery
• High risk patients frequently present with extensive disease,
and complete resection has been associated with long-term
neurologic sequelae.
• Preferred approach: Defer resection until after induction
chemotherapy.
• Surgery usually is performed 13 to 18 weeks after initiation
of chemotherapy.
Management: High Risk
Chemotherapy
Usually includes a combination of drugs
• Cyclophosphamide or ifosfamide, Platinum, Vincristine,
Doxorubicin, Etoposide, Topotecan, Busulfan & melphalan
• The most common combination of drugs includes platinum,
cyclophosphamide/ifosfamide, doxorubicin, and etoposide.
• I-131 is sometimes included in consolidative regimens;
therapeutic doses typically necessitate stem cell rescue.
• Examples: N6, N7, POG 9340/41/42, CCG 3891, N4SE etc.
Management: High Risk
Maintenance
• Maintenance therapy is biological and immunotherapy
targeting minimal residual disease (MRD).
• 13-cis-retinoic acid is given as a monthly 14-day cycles for 6
months.
• The addition of immunotherapy using the chimeric antibody
ch14.18 directed at the neuroblastoma tumor antigen GD2,
combined with GM-CSF and interleukin-2 (IL-2) also
significantly improves survival.1, 2
- Given as monthly cycles for 5-6 cycles.
Management: High Risk
1. Yu et al. COG ANBL0032. NEJM 2010
2. Cheung et al. JCO 2012
• A risk category suggested by the INRG
• Includes
- L1/L2 disease, maturing GN or intermixed GNB
- L1 all histologies with non amplified MYCN
- MS disease without MYCN amplification or 11q aberration
• For a subset of these patients, observation alone with surgery
reserved for persistent/progressive disease is a reasonable
approach that spares >80% patients a surgery.1
• Some patients may require radiotherapy for rapidly
progressive disease causing mass effect.
Management: Very Low Risk
Nuchtern JG et al. Ann Surg 2012
Role of Radiotherapy
• Neuroblastoma is a radiosensitive tumor.
• However, given the long term survival that is often
achievable, it is attempted to keep radiation requirement as
low as possible.
Uses
• Indicated in certain patients with Low and Intermediate risk
disease, and for most patients with High risk disease.
• Mass effect from a rapidly enlarging tumor can respond
dramatically to radiation therapy.
• It also plays an important role in the palliative management
of patients with end-stage symptomatic disease.
Low Risk Neuroblastoma
• More than 90% overall survival with surgery alone.
• Radiotherapy not indicated in INSS Stage 1 or 2.
• Stage 4S/MS
- Hepatomegaly causing significant respiratory compromise
- 3 - 6 Gy @ 1.5 Gy/#
- Kidneys and ovaries to be shielded.
Intermediate Risk Neuroblastoma
• RT was previously employed as a standard component of
multi-modality treatment.
• With improvements in systemic therapy, it was seen that RT
may be omitted in patients who have no residual disease
following initial treatment.
(Induction chemotherapy 4-8 months → Surgery)
• For patients with residual disease, adjuvant RT is
recommended; typically upto 21Gy/14# (1.5 Gy/#).
High Risk Neuroblastoma
• Generally advanced disease (regional + distant)
Intensive induction
chemotherapy
Surgery
Consolidation
chemotherapy
+
Stem cell rescue
Radiotherapy
Maintenance
therapy
• Adjuvant RT is given to a total dose of upto 21.6 Gy/12# @ 1.8
Gy/# for GTR and a boost upto 36 Gy for residual disease.1
1. COG 0532 protocol
2D Planning
• All available information (radiological, clinical, intra-
operative) to be used to ascertain extent of disease.
• Portals should include residual tumor after chemotherapy
with at least 2 cm margin from the tumor to the block edge.
• Regional LN should be covered if radiologically or
pathologically involved at any time during the disease
course.
• Parallel opposed AP-PA fields may be sufficient in many
cases, with occasional plans requiring a third field.
Radiation portal for a
child with Left adrenal
disease.
• Ipsilateral kidney to
be spared as far as
feasible with
generous inclusion
of para-aortic nodes.
• Medially the field
border should cross
the midline so as to
homogenously treat
the spine.
3D Conformal planning
• GTV / Tumor bed: Post-chemotherapy tumor volume with
editing at uninvolved normal structures.
• CTV: GTV + 0.5mm; CTV should not be edited at
uninvolved organs.
• ITV: 5mm is generally sufficient with 4D-CT; upto 1cm may
be necessary otherwise.
• PTV: 5-10mm depending on institutional protocols.
Target volumes (specific cases)
Site Target
Orbital metastases Entire orbit
Liver mets Entire liver need not be included, but
adequate margins must be taken (incl.
those for organ motion).
Relapsed or refractory cases
• No effective strategies available to salvage recurrent
or refractory disease.
• Goal of treatment is palliation
- Chemotherapy
- Radiotherapy
- Radionuclide therapy (I-131)
- Retinoids & immunotherapy (13-cis-retinoid acid/ch14.18)
- Clinical trial (combination of the above; novel agents)
Iodine – 131 MIBG therapy
• May be used for Stage III or IV neuroblastoma with MIBG-
avid lesions at diagnostic I-123 MIBG or I-131 MIBG
scintigraphy.
- Generally incorporated after surgery as high dose treatments
(12-18 mCi/kg) with stem cell rescue.
- Utility doubted in view of toxicity and poor tolerance (Nausea,
vomiting, anorexia, fatigue, fever, stomatitis)
• Also tested in small retrospective and phase I/II studies for
newly diagnosed neuroblastoma as induction treatment prior
to surgical resection.
- Good response rates noted; untested in phase III trials.
Iodine – 131 MIBG therapy
• Contraindications
- Renal failure requiring dialysis and expected life less than
3 months unless in case of refractory bone pain.
- GFR less than 30 mL/min.
Survival of 2196 consecutive NB patients
treated under CCG and POG protocols
Outcomes
Role of Screening
Rationale
• Relatively good prognosis of infants diagnosed with early-stage
neuroblastoma + High number of children with metastatic disease
(i.e. advanced stage) at diagnosis.
However..
• Large randomized studies have failed to demonstrate a survival
benefit with screening.
• Screen detected disease tends to be favorable with good outcomes
(80 – 85%) while those negative for screening who develop Nb
tend to develop disseminated disease with unfavorable histology.
No Role
Conclusion
• A treatable malignancy, but poor outcomes for bad biology
despite advances in oncology.
• High Risk children continue to have poor outcomes despite
aggressive treatment, while some patients with very low risk
disease may be safely observed.
• Surgery remains the cornerstone of treatment; chemotherapy
and radiotherapy form supportive pillars.
(more recently, immunotherapy also employed).
• Early detection remains a challenge; improving treatment
protocols is the present direction of research.
Thank You

More Related Content

What's hot (20)

Biliary Atresia
Biliary AtresiaBiliary Atresia
Biliary Atresia
 
Neuroblastoma presentation
Neuroblastoma presentationNeuroblastoma presentation
Neuroblastoma presentation
 
Renal cell carcinoma
Renal cell carcinomaRenal cell carcinoma
Renal cell carcinoma
 
Neuroblastoma
NeuroblastomaNeuroblastoma
Neuroblastoma
 
Acute Lymphoblastic Leukemia
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
 
Soft tissue sarcoma
Soft tissue sarcomaSoft tissue sarcoma
Soft tissue sarcoma
 
Bladder carcinoma
Bladder carcinomaBladder carcinoma
Bladder carcinoma
 
Paediatric oncology
Paediatric oncologyPaediatric oncology
Paediatric oncology
 
Neuroblastoma
Neuroblastoma Neuroblastoma
Neuroblastoma
 
Neuroblastoma
NeuroblastomaNeuroblastoma
Neuroblastoma
 
Lymphoma in children Dr G.Rajkumar
Lymphoma in children Dr G.RajkumarLymphoma in children Dr G.Rajkumar
Lymphoma in children Dr G.Rajkumar
 
Neuroblastoma
NeuroblastomaNeuroblastoma
Neuroblastoma
 
Solid tumors in children 2021
Solid tumors in children 2021Solid tumors in children 2021
Solid tumors in children 2021
 
Carcinoma rectum (Rectal Cancer)
Carcinoma rectum (Rectal Cancer)Carcinoma rectum (Rectal Cancer)
Carcinoma rectum (Rectal Cancer)
 
Neuroblastoma and Nephroblastoma
Neuroblastoma and NephroblastomaNeuroblastoma and Nephroblastoma
Neuroblastoma and Nephroblastoma
 
Multiple endocrine neoplasia (men) syndromes
Multiple endocrine neoplasia (men) syndromesMultiple endocrine neoplasia (men) syndromes
Multiple endocrine neoplasia (men) syndromes
 
Esophageal ca
Esophageal caEsophageal ca
Esophageal ca
 
testicular tumors
testicular tumorstesticular tumors
testicular tumors
 
Wilms' Tumor
Wilms' TumorWilms' Tumor
Wilms' Tumor
 
Wilms tumor
Wilms tumorWilms tumor
Wilms tumor
 

Similar to Neuroblastoma

Brain tumor dr. abeer elsayed
Brain tumor dr. abeer elsayedBrain tumor dr. abeer elsayed
Brain tumor dr. abeer elsayedAbeer Ibrahim
 
Soft tissue tumor
Soft tissue tumorSoft tissue tumor
Soft tissue tumormanoj das
 
Pancreatic neuro endocrine tumours
Pancreatic neuro endocrine tumoursPancreatic neuro endocrine tumours
Pancreatic neuro endocrine tumoursdamuluri ramu
 
Central nervous system tumors in children
Central nervous system tumors in childrenCentral nervous system tumors in children
Central nervous system tumors in childrenSasikumar Sambasivam
 
Solid pediatric tumour - wilms,neuroblastoma,hepatoblastoma, GCT
Solid pediatric tumour - wilms,neuroblastoma,hepatoblastoma, GCTSolid pediatric tumour - wilms,neuroblastoma,hepatoblastoma, GCT
Solid pediatric tumour - wilms,neuroblastoma,hepatoblastoma, GCTsurveshkumarGupta1
 
2021 WHO Classification of brain tumours.pptx
2021 WHO Classification of brain tumours.pptx2021 WHO Classification of brain tumours.pptx
2021 WHO Classification of brain tumours.pptxRejoyceAnto
 
Management of Low Grade Glioma
Management of Low Grade GliomaManagement of Low Grade Glioma
Management of Low Grade GliomaShreya Singh
 
Evolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumorsEvolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumorsAnil Gupta
 
Neuro-oncology for the Radiation Oncologist - Part 2 - October 2015
Neuro-oncology for the Radiation Oncologist - Part 2 - October 2015Neuro-oncology for the Radiation Oncologist - Part 2 - October 2015
Neuro-oncology for the Radiation Oncologist - Part 2 - October 2015Emil Lou, M.D., Ph.D, FACP
 
Neoplasia & Carcinogenesis
Neoplasia & CarcinogenesisNeoplasia & Carcinogenesis
Neoplasia & CarcinogenesisMuhammad Helmi
 
1 soft tissue sarcomas
1 soft tissue sarcomas1 soft tissue sarcomas
1 soft tissue sarcomasellein092629
 
Neuroblastoma & Wilms tumor.pptx
Neuroblastoma & Wilms tumor.pptxNeuroblastoma & Wilms tumor.pptx
Neuroblastoma & Wilms tumor.pptxIrfanNashad1
 

Similar to Neuroblastoma (20)

Brain tumor dr. abeer elsayed
Brain tumor dr. abeer elsayedBrain tumor dr. abeer elsayed
Brain tumor dr. abeer elsayed
 
Neuroblastoma a tough nut to crack ?
Neuroblastoma a tough nut to crack ?Neuroblastoma a tough nut to crack ?
Neuroblastoma a tough nut to crack ?
 
Medulloblastoma
MedulloblastomaMedulloblastoma
Medulloblastoma
 
Meningioma- Dr Kiran
Meningioma- Dr KiranMeningioma- Dr Kiran
Meningioma- Dr Kiran
 
Soft tissue tumor
Soft tissue tumorSoft tissue tumor
Soft tissue tumor
 
Pancreatic neuro endocrine tumours
Pancreatic neuro endocrine tumoursPancreatic neuro endocrine tumours
Pancreatic neuro endocrine tumours
 
Glioma
GliomaGlioma
Glioma
 
Central nervous system tumors in children
Central nervous system tumors in childrenCentral nervous system tumors in children
Central nervous system tumors in children
 
Solid pediatric tumour - wilms,neuroblastoma,hepatoblastoma, GCT
Solid pediatric tumour - wilms,neuroblastoma,hepatoblastoma, GCTSolid pediatric tumour - wilms,neuroblastoma,hepatoblastoma, GCT
Solid pediatric tumour - wilms,neuroblastoma,hepatoblastoma, GCT
 
2021 WHO Classification of brain tumours.pptx
2021 WHO Classification of brain tumours.pptx2021 WHO Classification of brain tumours.pptx
2021 WHO Classification of brain tumours.pptx
 
Spinal Tumor.pptx
Spinal Tumor.pptxSpinal Tumor.pptx
Spinal Tumor.pptx
 
Management of Low Grade Glioma
Management of Low Grade GliomaManagement of Low Grade Glioma
Management of Low Grade Glioma
 
Wilms tumors
Wilms tumorsWilms tumors
Wilms tumors
 
Evolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumorsEvolution of treatment strategies of brain tumors
Evolution of treatment strategies of brain tumors
 
NB.pptx
NB.pptxNB.pptx
NB.pptx
 
Neuro-oncology for the Radiation Oncologist - Part 2 - October 2015
Neuro-oncology for the Radiation Oncologist - Part 2 - October 2015Neuro-oncology for the Radiation Oncologist - Part 2 - October 2015
Neuro-oncology for the Radiation Oncologist - Part 2 - October 2015
 
Neoplasia & Carcinogenesis
Neoplasia & CarcinogenesisNeoplasia & Carcinogenesis
Neoplasia & Carcinogenesis
 
Carcinoma Thyroid
Carcinoma ThyroidCarcinoma Thyroid
Carcinoma Thyroid
 
1 soft tissue sarcomas
1 soft tissue sarcomas1 soft tissue sarcomas
1 soft tissue sarcomas
 
Neuroblastoma & Wilms tumor.pptx
Neuroblastoma & Wilms tumor.pptxNeuroblastoma & Wilms tumor.pptx
Neuroblastoma & Wilms tumor.pptx
 

More from Animesh Agrawal

Radiotherapy techniques for Breast Cancer
Radiotherapy techniques for Breast CancerRadiotherapy techniques for Breast Cancer
Radiotherapy techniques for Breast CancerAnimesh Agrawal
 
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLC
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLCJournal club: Durvalumab as Consolidation therapy in Advanced NSCLC
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLCAnimesh Agrawal
 
Treatment of breast cancer
Treatment of breast cancerTreatment of breast cancer
Treatment of breast cancerAnimesh Agrawal
 
Cervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniquesCervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniquesAnimesh Agrawal
 
Management of advanced prostate carcinoma
Management of advanced prostate carcinomaManagement of advanced prostate carcinoma
Management of advanced prostate carcinomaAnimesh Agrawal
 
Management of lower Gastrointestinal malignancies
Management of lower Gastrointestinal malignanciesManagement of lower Gastrointestinal malignancies
Management of lower Gastrointestinal malignanciesAnimesh Agrawal
 
Management of Carcinoma Larynx
Management of Carcinoma LarynxManagement of Carcinoma Larynx
Management of Carcinoma LarynxAnimesh Agrawal
 

More from Animesh Agrawal (9)

Radiotherapy techniques for Breast Cancer
Radiotherapy techniques for Breast CancerRadiotherapy techniques for Breast Cancer
Radiotherapy techniques for Breast Cancer
 
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLC
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLCJournal club: Durvalumab as Consolidation therapy in Advanced NSCLC
Journal club: Durvalumab as Consolidation therapy in Advanced NSCLC
 
Treatment of breast cancer
Treatment of breast cancerTreatment of breast cancer
Treatment of breast cancer
 
Breast anatomy
Breast anatomyBreast anatomy
Breast anatomy
 
Cervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniquesCervix External Beam Radiotherapy techniques
Cervix External Beam Radiotherapy techniques
 
Penile carcinoma
Penile carcinomaPenile carcinoma
Penile carcinoma
 
Management of advanced prostate carcinoma
Management of advanced prostate carcinomaManagement of advanced prostate carcinoma
Management of advanced prostate carcinoma
 
Management of lower Gastrointestinal malignancies
Management of lower Gastrointestinal malignanciesManagement of lower Gastrointestinal malignancies
Management of lower Gastrointestinal malignancies
 
Management of Carcinoma Larynx
Management of Carcinoma LarynxManagement of Carcinoma Larynx
Management of Carcinoma Larynx
 

Recently uploaded

FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets barmohitRahangdale
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?Ryan Addison
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxkitati1
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingAnonymous
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxsumanchaulagain3
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisNilofarRasheed1
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).kishan singh tomar
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 

Recently uploaded (20)

FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
Role of Soap based and synthetic or syndets bar
Role of  Soap based and synthetic or syndets barRole of  Soap based and synthetic or syndets bar
Role of Soap based and synthetic or syndets bar
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?The Importance of Mental Health: Why is Mental Health Important?
The Importance of Mental Health: Why is Mental Health Important?
 
Microbiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptxMicrobiology lecture presentation-1.pptx
Microbiology lecture presentation-1.pptx
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
General_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_WellbeingGeneral_Studies_Presentation_Health_and_Wellbeing
General_Studies_Presentation_Health_and_Wellbeing
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
World-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptxWorld-TB-Day-2023_Presentation_English.pptx
World-TB-Day-2023_Presentation_English.pptx
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
Physiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid ArthritisPhysiotherapy Management of Rheumatoid Arthritis
Physiotherapy Management of Rheumatoid Arthritis
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
concept of total quality management (TQM).
concept of total quality management (TQM).concept of total quality management (TQM).
concept of total quality management (TQM).
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 

Neuroblastoma

  • 1. Neuroblastoma 17.10.18 By Dr Animesh Agrawal Moderator Dr Shagun Misra
  • 2. Contents • Introduction • Clinical Presentation • Pathology & Risk grouping • Diagnostic workup • Prognostic factors • Management • Role of Screening
  • 3. Introduction • Arise from primitive adrenergic neuroblasts of neural crest tissue in the sympathetic ganglion. • 4th most common malignancy in children • Most common malignancy in children <18 mo • Median age at diagnosis – 22 months • Clinical heterogeneity • Spectrum of disease includes spontaneous maturation to rapid metastatic disease progression.
  • 4. • Adrenal medulla (35%) • Para-spinal ganglia lower thoracic and abdominal (30%) • Posterior mediastinum (19%) • Pelvic ganglia (2%) • Cervical ganglia (1%) • Metastases - Bone, bone marrow, liver, lymph node and skin Location
  • 5. Clinical presentation • Pain - Most common presenting symptom - Due to local spread &/or metastatic disease • Abdominal lump • Respiratory compromise: Esp. in young infants with massive hepatomegaly. • Others - Horner’s syndrome (neck mass) - Spinal cord compression - Cytopenias (marrow involvement) - Blueberry muffin sign (skin involvement) - Bowel/bladder dysfunction (pelvic mass) - Opsoclonus–myoclonus syndrome (truncal ataxia and cerebellar encephalopathy). - Proptosis/ecchymoses: Orbital mets • Constitutional symptoms: Anorexia, weight loss, malaise, fever
  • 6. • Mimic pheochromocytoma: - Paroxysmal hypertension, palpitations, flushing, and headache. • Severe watery diarrhea and hypokalemia (due to secretion of vasoactive intestinal peptide by the tumor)
  • 7. More than 70% of patients with neuroblastoma present with metastases at diagnosis.
  • 8. Neuroblastoma vs Wilm’s Tumor • Median age of presentation for NB is ~1.5 yrs vs > 3 yrs for Wilms • Neuroblastoma often crosses midline (Wilms does not). • Wilms patients appear healthy vs. NB patients appear sick • Neuroblastoma (85%) is more likely to exhibit calcifications vs 5 – 10% in Wilm’s. • NB rarely metastasizes to the lungs (frequent in Wilm’s tumor). • Wilms arises from & destroys the kidney; NB displaces the kidney.
  • 9. Pathology • Classic subtypes - Neuroblastoma - Ganglioneuroblastoma - Ganglioneuroma • Neuroblastoma - Small uniform cells - Hyperchromatic nuclei & scant cytoplasm - Homer Wright pseudorosette - Necrosis and calcification - Mature & intermediate differentiation ganglion cells increasing differentiation
  • 10. • Shimada system - Classified tumors into good or poor prognosis groups based on:  Stromal component (Stroma rich or poor)  Grade of differentiation - Stroma rich, well differentiated - Stroma rich, intermixed - Stroma rich, nodular - Stroma poor, differentiating - Stroma Poor, undifferentiated  MKI (Mitosis – Karyorrhexis Index)  Age (< 18mo, 18 – 60mo, > 60mo) Shimada et al. JNCI 1984 Histologic classification
  • 11. Shimada et al. JNCI 1984 Histologic classification
  • 12. Histologic classification • International Neuroblastoma Pathology Committee (INPC) - Based on the Shimada system with minor modifications Shimada et al. Cancer 1999
  • 13. INPC classification: Favorable histology Age Tumor subtype MKI Any GNB, nodular* NA GNB, intermixed NA GN NA < 18 mo Poorly differentiated NB Low to Intermediate Differentiating NB Intermediate 18 - 60 mo Differentiating NB Low * All nodules of NB must have favourable histology * Nodule: Presence of grossly discrete masses of stroma-poor Nb trapped in mature matrix
  • 14. Age Tumor subtype MKI Age Undifferentiated NB Any Poorly differentiated NB High Differentiating NB High Ganglioneuroblastoma, nodular* NA 18 – 60 mo Poorly differentiated NB Low to Intermediate Differentiating NB Intermediate ≥ 60 mo Differentiating NB Any *At least one nodule of NB must have unfavourable histology INPC classification: Unfavorable histology
  • 15. Diagnosis Laboratory Evaluation • Routine haematological investigations - Hemogram - Biochemistry • Increased levels of urinary metabolites of catecholamines, Vanillylmandelic acid (VMA) Homovanillic acid (HVA) - Seen in > 90% patients. • May consider: NSE, Chromogranin A (CgA)
  • 16. Imaging • Plain radiographs (calcified abdominal or posterior mediastinal mass.) • USG Abdomen • CE CT/MRI more useful - Intratumoral calcifications, vascular encasement, or both on preoperative imaging may help distinguish neuroblastoma from Wilms tumor - INRG staging depends on radiological parameters for risk stratification. • I-123 MIBG (meta-iodo-benzyl-guanidine) + Tc-99m bone scans for staging.
  • 17. Biopsy • Tissue diagnosis is an essential step, except in cases with +ve bone marrow and urinary excretion of catecholamine metabolites. • IHC and tumor cytogenetics form an integral part of deciding management. - MYCN amplification (~ 1/3rd) - 11q aberrations - DNA ploidy (hyperdiploid carries a better prognosis) - 1p deletion (~ 2/3rd)
  • 18. Other Markers • NSE & CgA (levels correlate with more advanced disease and worse prognosis) • NB84 (highly sensitive; less specific) • CD56 (diffuse positivity indicates more blastic component) • S100 (diffuse positivity indicates better differentiation) Negative for: • CD45, CD99, EMA, CK, desmin, myogenin
  • 19. Bone marrow aspiration and biopsy • Bone marrow involvement is seen in ~ 40% patients at diagnosis. • If blood or urine levels of catecholamines are increased, then finding cancer cells in a bone marrow sample is enough to diagnose neuroblastoma (without getting a biopsy of the main tumor). • INSS recommends two aspirations and biopsies from bilateral sites; biopsy is not required for infants < 6m age.
  • 21. • Historically the most commonly used. • Postoperative system. • Based on both extent of resection and disease extent.
  • 22. I Localized; GTR (R0/R1) IIA Localized; < GTR; N0 IIB Localized; ipsilateral Node +ve (C/L –ve) III Unresectable disease crossing midline or C/L nodes +ve IV Distant spread: Nodes, bone marrow/bone, liver, skin or others IV-S Localized; dissemination limited to skin, liver or marrow (age < 1y) International Neuroblastoma Staging system (INSS)
  • 23. INSS • Based on the INSS, COG stratifies patients into Low, Intermediate and High risk1. • Further management is decided based on the above. 1. Maris JM, Matthay KK. JCO 1999
  • 24. Limitations of INSS • Postoperative system, so pre-operative staging/prognostication cannot be done. • In an era with improved systemic and supportive therapy, more patients now receive neoadjuvant treatment. • INSS staging is done only after upfront surgical resection. This is often not possible due to extensive local disease/widespread metastases.
  • 25. International Neuroblastoma Risk Group (INRG) Staging system L1 Localized tumor not involving vital structures as defined by the list of IDRFs and confined to one body compartment L2 Locoregional tumor with presence of one or more IDRFs M Distant metastatic disease (except stage MS) MS Metastatic disease in children < 18 months with metastases confined to skin, liver, and/or bone marrow (< 10%) • Preoperative staging and risk assessment.
  • 26. Image defined risk factors (IDRFs) • Surgical risk factors identified at diagnosis, such that a complete resection is unsafe. • Outlined in a Task Force Report by the INRG1: - Multi-compartment disease - Encasement of major vessels (carotid, vertebral, IJV, subclavian, aorta, SVC/IVC, SMA, celiac trunk, renal pedicles, iliac vessels) - Contiguous involvement of other organs/structures (base of skull, pericardium, diaphragm, kidney, liver, porta hepatis, hepatoduodenal ligament, duodeno-pancreatic block, mesentery) - Intraspinal extension (> 1/3rd) - Airway compression (trachea/principal bronchi) 1. Monclair et al. JCO 2009
  • 27. INRG Classification system • Along with staging, the task force also suggested a risk stratification system integrating several parameters, namely: • The risk groups are Very low, Low, Intermeditate and High. Cohn et al. INRG Task Force; JCO 2009 INRG Stage L1 > L2 > M Age < 18 months Histologic category GN > GNB > NB Grade of tumor differentiation Differentiating N-myc status Not amplified 11q aberrations Absence Tumor cell ploidy Hyperdiploidy
  • 28. INRG Classification System Cohn et al. INRG Task Force; JCO 2009
  • 29. To summarize.. • Staging can be either INSS based, i.e. post op - Risk stratification is then based on the COG approach (older, more commonly followed) - Low, Intermediate, High • Or the INRG approach may be used i.e. preoperative (more recent, gradually being adopted) - Risk stratification being as proposed by the INRG - Very Low, Low, Intermediate, High
  • 30. Prognostic factor Favorable Unfavorable Survival Favorable Unfavorable • Age • Stage • Pathology (Shimada) • Ferritin • NSE • Urine VMA/HVA • N-myc • DNA index • 1p deletion < 2 yrs 1,2 , 4s Favourable <143 ng/ml <100 <1 single copy > 1.1 Absent > 2 yrs 3, 4 Unfavorable > 143 ng/ml < 143 ng/ml > 1 Amplified 1 Present 77% 90-100% 90% 83% 79% 84% 70% 100% 90% 38% 30-50% 23% 19% 10% 44% 5% 10% 10% * Matthay KK. CA Cancer J Clin 1995 Impact on survival of various prognostic factors
  • 32. Treatment Options • Surgery • Chemotherapy • Radiation therapy • High-dose chemotherapy/radiation therapy and stem cell transplant (HDC/SCT rescue) • Retinoid therapy/Immunotherapy
  • 33. Management: Low Risk • Low risk (about 50%) • Surgery alone for stage 1 or 2 disease may be sufficient. • Short course chemotherapy for symptomatic cord compression or respiratory compromise; may also consider short course radiotherapy for this purpose. • Stage 4S: supportive care or short course of chemotherapy • Survival - 90-95% • Patients with MYCN amplification or low DNA index may require adjuvant therapy, and management should be decided based on the extent of resection and other risk factors.
  • 34. • About 10-15% of new cases • Primary resection + standard dose multiagent chemotherapy for 4-8 months • In disease that in unresectable or has instraspinal extension, neoadjuvant chemotherapy may be given prior to resection to allow safer and more complete resection. • Survival > 80% • Radiotherapy may be indicated for certain patients. Management: Intermediate Risk
  • 35. Chemotherapy regimen (COG A3961 PROTOCOL) Course Day Drugs 1 0 Carboplatin – Etoposide 1 Etoposide 2 Etoposide 2 21 Carboplatin – Cyclophosphamide – Doxorubicin 3 42 Cyclophosphamide – Etoposide 43 Etoposide 44 Etoposide 4 63 Carboplatin – Etoposide – Doxorubicin 64 Etoposide 65 Etoposide Management: Intermediate Risk
  • 36. Chemotherapy regimen (contd) Course Day Drugs 5 84 Cyclophosphamide – Etoposide 85 Etoposide 86 Etoposide 6 105 Carboplatin – Cyclophosphamide – Doxorubicin 7 126 Carboplatin – Etoposide 127 Etoposide 128 Etoposide 8 147 Carboplatin – Etoposide – Doxorubicin Management: Intermediate Risk • Patients with favourable histology IR disease receive only the 1st 4 courses.
  • 37. Chemotherapy regimen (contd) Management: Intermediate Risk Drug dosages Carboplatin 560 mg/m2 or 18 mg/kg iv over 1 hour Etoposide 120 mg/m2 or 4 mg/kg iv over 2 hours Cyclophosphamide 1000 mg/m2 or 33 mg/kg iv over 1 hour Doxorubicin Doxorubicin 30 mg/m2 or 1 mg/kg iv over 15-60 minutes COG A3961 protocol
  • 38. • Four general components 1. Induction chemotherapy 2. Surgical resection of all gross disease 3. Consolidation therapy- which generally includes Myeloablative chemotherapy with stem cell rescue and Radiation to the tumor bed. 4. Management of Minimal Residual Disease • Radiotherapy - Local RT for bulky primary (complementary to surgery) - TBI: as part of myeloablative conditioning regimen if HDC/ASCT is planned. Management: High Risk
  • 39. Surgery • High risk patients frequently present with extensive disease, and complete resection has been associated with long-term neurologic sequelae. • Preferred approach: Defer resection until after induction chemotherapy. • Surgery usually is performed 13 to 18 weeks after initiation of chemotherapy. Management: High Risk
  • 40. Chemotherapy Usually includes a combination of drugs • Cyclophosphamide or ifosfamide, Platinum, Vincristine, Doxorubicin, Etoposide, Topotecan, Busulfan & melphalan • The most common combination of drugs includes platinum, cyclophosphamide/ifosfamide, doxorubicin, and etoposide. • I-131 is sometimes included in consolidative regimens; therapeutic doses typically necessitate stem cell rescue. • Examples: N6, N7, POG 9340/41/42, CCG 3891, N4SE etc. Management: High Risk
  • 41. Maintenance • Maintenance therapy is biological and immunotherapy targeting minimal residual disease (MRD). • 13-cis-retinoic acid is given as a monthly 14-day cycles for 6 months. • The addition of immunotherapy using the chimeric antibody ch14.18 directed at the neuroblastoma tumor antigen GD2, combined with GM-CSF and interleukin-2 (IL-2) also significantly improves survival.1, 2 - Given as monthly cycles for 5-6 cycles. Management: High Risk 1. Yu et al. COG ANBL0032. NEJM 2010 2. Cheung et al. JCO 2012
  • 42. • A risk category suggested by the INRG • Includes - L1/L2 disease, maturing GN or intermixed GNB - L1 all histologies with non amplified MYCN - MS disease without MYCN amplification or 11q aberration • For a subset of these patients, observation alone with surgery reserved for persistent/progressive disease is a reasonable approach that spares >80% patients a surgery.1 • Some patients may require radiotherapy for rapidly progressive disease causing mass effect. Management: Very Low Risk Nuchtern JG et al. Ann Surg 2012
  • 44. • Neuroblastoma is a radiosensitive tumor. • However, given the long term survival that is often achievable, it is attempted to keep radiation requirement as low as possible. Uses • Indicated in certain patients with Low and Intermediate risk disease, and for most patients with High risk disease. • Mass effect from a rapidly enlarging tumor can respond dramatically to radiation therapy. • It also plays an important role in the palliative management of patients with end-stage symptomatic disease.
  • 45. Low Risk Neuroblastoma • More than 90% overall survival with surgery alone. • Radiotherapy not indicated in INSS Stage 1 or 2. • Stage 4S/MS - Hepatomegaly causing significant respiratory compromise - 3 - 6 Gy @ 1.5 Gy/# - Kidneys and ovaries to be shielded.
  • 46. Intermediate Risk Neuroblastoma • RT was previously employed as a standard component of multi-modality treatment. • With improvements in systemic therapy, it was seen that RT may be omitted in patients who have no residual disease following initial treatment. (Induction chemotherapy 4-8 months → Surgery) • For patients with residual disease, adjuvant RT is recommended; typically upto 21Gy/14# (1.5 Gy/#).
  • 47. High Risk Neuroblastoma • Generally advanced disease (regional + distant) Intensive induction chemotherapy Surgery Consolidation chemotherapy + Stem cell rescue Radiotherapy Maintenance therapy • Adjuvant RT is given to a total dose of upto 21.6 Gy/12# @ 1.8 Gy/# for GTR and a boost upto 36 Gy for residual disease.1 1. COG 0532 protocol
  • 48. 2D Planning • All available information (radiological, clinical, intra- operative) to be used to ascertain extent of disease. • Portals should include residual tumor after chemotherapy with at least 2 cm margin from the tumor to the block edge. • Regional LN should be covered if radiologically or pathologically involved at any time during the disease course. • Parallel opposed AP-PA fields may be sufficient in many cases, with occasional plans requiring a third field.
  • 49. Radiation portal for a child with Left adrenal disease. • Ipsilateral kidney to be spared as far as feasible with generous inclusion of para-aortic nodes. • Medially the field border should cross the midline so as to homogenously treat the spine.
  • 50. 3D Conformal planning • GTV / Tumor bed: Post-chemotherapy tumor volume with editing at uninvolved normal structures. • CTV: GTV + 0.5mm; CTV should not be edited at uninvolved organs. • ITV: 5mm is generally sufficient with 4D-CT; upto 1cm may be necessary otherwise. • PTV: 5-10mm depending on institutional protocols.
  • 51. Target volumes (specific cases) Site Target Orbital metastases Entire orbit Liver mets Entire liver need not be included, but adequate margins must be taken (incl. those for organ motion).
  • 52. Relapsed or refractory cases • No effective strategies available to salvage recurrent or refractory disease. • Goal of treatment is palliation - Chemotherapy - Radiotherapy - Radionuclide therapy (I-131) - Retinoids & immunotherapy (13-cis-retinoid acid/ch14.18) - Clinical trial (combination of the above; novel agents)
  • 53. Iodine – 131 MIBG therapy • May be used for Stage III or IV neuroblastoma with MIBG- avid lesions at diagnostic I-123 MIBG or I-131 MIBG scintigraphy. - Generally incorporated after surgery as high dose treatments (12-18 mCi/kg) with stem cell rescue. - Utility doubted in view of toxicity and poor tolerance (Nausea, vomiting, anorexia, fatigue, fever, stomatitis) • Also tested in small retrospective and phase I/II studies for newly diagnosed neuroblastoma as induction treatment prior to surgical resection. - Good response rates noted; untested in phase III trials.
  • 54. Iodine – 131 MIBG therapy • Contraindications - Renal failure requiring dialysis and expected life less than 3 months unless in case of refractory bone pain. - GFR less than 30 mL/min.
  • 55. Survival of 2196 consecutive NB patients treated under CCG and POG protocols Outcomes
  • 56. Role of Screening Rationale • Relatively good prognosis of infants diagnosed with early-stage neuroblastoma + High number of children with metastatic disease (i.e. advanced stage) at diagnosis. However.. • Large randomized studies have failed to demonstrate a survival benefit with screening. • Screen detected disease tends to be favorable with good outcomes (80 – 85%) while those negative for screening who develop Nb tend to develop disseminated disease with unfavorable histology. No Role
  • 57. Conclusion • A treatable malignancy, but poor outcomes for bad biology despite advances in oncology. • High Risk children continue to have poor outcomes despite aggressive treatment, while some patients with very low risk disease may be safely observed. • Surgery remains the cornerstone of treatment; chemotherapy and radiotherapy form supportive pillars. (more recently, immunotherapy also employed). • Early detection remains a challenge; improving treatment protocols is the present direction of research.